Inmunohistoquímica diagnóstica en dermatopatología tumoral maligna

Actas Dermo-Sifiliograficas

Volumn 88, Issue 5, 1997, Pages 233-251

  Fernández, Javier Fraga ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Immunohistochemistry; Malignant cutaneous neoplasms

Indexed keywords

EID: 0042346258     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (196)

1. Gown AM, De Wever N, Battifora H. Microwave-based antigenic unmasking: a revolutionary new technique four routine immunohistochemistry. Appl Immunohistochem 1993;1:256-66.
2. Cattoretti G, Sourmeijer AJH. Antigen unmasking on formalin-fixed paraffin-embedded tissues using microwaves: a review. Adv Anat Pathol 1995;2:2-9.
3. Miller K, Auld J, Jessup E, Rhodes A, Asthon-Key M. Antigen unmasking in formalin-fixed routinely processed paraffin wax-embedded sections by pressure cooking: a comparison with microwave oven healting and traditional methods. Adv Anat Pathol 1995;2:60-4.
4. Cockerell CJ, Sexton FM. Evaluation of small-cell neoplasms of the skin. Clin Dermatol 1991;9:227-33.
5. Wick MR, Swanson PE, Ritter JH, Fitzgibbon JF. The immunohistology of cutaneous neoplasms: a practical perspective. J Cutan Pathol 1993;20:481-97.
6. Wallace ML, Smoller BR. Immunohistochemistry in diagnostic dermatopathology. J Am Acad Dermatol 1996;34:163-83.
7. Ratner D, Nelson B, Brown M, Johson TM. Merkel cell carcinoma. J Am Acad Dermatol 1993;29:143-56.
8. Wick MR, Scheüthauer BW. Primary neuroendocrine carcinoma of the skin. En: Wick MR (eds): Pathology of unusual malignant cutaneous tumors New York, NY: Marcel Dekker Inc, 1985;107-80.
9. Silva EG, Mackay B, Goepfert H, Burgess MA, Fields RS. Endocrine carcinoma of the skin (Merkel-cell carcinoma). Pathol Annu 1984;19:1-30.
10. Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972;105:107-10.
11. Tang CK, Toker C. Trabecular carcinoma of the skin: an ultrastructural study. Cancer 1978;42:2311-21.
12. Sibley RK, Dahl D. Primary neuroendocrine (Merkel cell?) carcinoma of the skin. II. An immunocytochemical study of 21 cases. Am J Surg Pathol 1985;9:109-16.
13. Drijkroningen M, De Wolf-Peeters C, Van Limbergen E, Desmet V. Merkel cell tumor of the skin: an immunohistochemical study. Hum Pathol 1986;17:301-7.
14. Gould E, Albores-Saavedra J, Smith W, Payne CM. Ecrine and squamous differentiation in Merkel cell carcinoma, an immunohistochemical study. An J Surg Pathol 1988;12:768-72.
15. Heenan PJ, Cole JM, Spagnolo DV. Primary cutaneous neuroendocrine carcinoma (Merkel cell tumor): an adnexal epithelial neoplasm. Am J Dermatopathol 1990;12:7-16.
16. Smith KJ, Skelton HG, Holland TT, Morgan AM, Lupton GP. Neuroendocrine (Merkel cell) carcinoma with and intraepidermal component. Am J Dermatopathol 1993;15:528-33.
17. Van Muijen GNP, Ruiter DJ, Warnaar SO. Intermediate filaments in Merkel cell tumors. Hum Pathol 1985;16:590-5.
18. Díaz JM, Fresno M, Díaz CJ, Floriano PL, Herrero-Zapatero A. Importancia de las diferentes citoqueratinas en el diagnóstico del carcinoma neuroendocrino de la piel (carcinoma de células de Merkel). Patología 1994;27:325-9.
19. Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
20. Moll I, Kuhn C, Moll R. Cytokeratin 20 is a general marker of cutaneous Merkel cells while certain neuronal proteins are absent. J Invest Dermatol 1995;104:910-5.
21. Miettinen M. Keratin 20. Immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol 1995;8:364-88.
22. Sibley RK, Rosai J, Foucar E, Dehner LP, Bosl G. Neuroendocrine (Merkel cell) carcinoma of the skin. A histologic and ultrastructural study of two cases. Am J Surg Pathol 1980;4:211-21.
23. Wick MR, Kaye VN, Sibley RK, Tyler R, Frizzera G. Primary neuroendocrine carcinoma and small-cell malignant lymphoma of the skin. A discriminant immunohistochemical comparison. J Cutan Pathol 1986;13:347-58.
24. Brinkschmidt C, Stalze P, Fahrenkamp AG et al. Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in Merkel cell carcinoma of the skin. Appl Immunohistochem 1995;3:37-44.
25. Gould VE, Wiedenmann B, Lee I et al. Synaptophysin expression in neuroendocrine neoplams as determined by immunocytochemistry. Am J Pathol 1987;126:243-57.
26. Hagn C, Schmid KW, Fischer-Colbrie R, Winkler H. Chromogranin A, B, and C in human adrenal medulla and endocrine tissues Lab Invest 1986;55:405-11.
27. Lloyd RV, Cano M, Rosa P, Hille A, Huttner WB. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol 1988;130:296-304.
28. Kirchmair R, Hogue-Angeletti R, Guitarrez J, Fischer-Colbrie R, Winkler H. Secretoneurin a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience 1993;53:359-65.
29. Revenga Arranz F, Rodríguez Peralto JL, Gil Martín R, Martínez González MA, Ballestín Carcavilla C, Iglesias Díez L. Tumor neuroendocrino cutáneo primario: estudio clinico-patológico de 8 casos. Actas Derinosifiliogr 1995;86:81-8.
30. Battifora H, Sliva EG. The use of antikeratin antibody in the immunohistochemical distinction between neuroendocrine (Merkel cell) carcinoma of the skin, lymphoma and oat cell carcinoma. Cancer 1986;58:1040-6.
31. Gould V, Moll R, Moll I, Lee I, Franke W. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias and neoplasias. Lab Invest 1985;52:334-53.
32. Foschin MP, Eusebi V. The spectrum of endocrine tumours of the skin. Curr Diag Pathol 1995;2:2-9.
33. Bayrou O, Avril MF, Charpentier P, Caillou B, Guillaume JC, Prade M. Primary neuroendocrine carcinoma the skin. J Am Acad Dermatol 1991;24:198-207.
34. Hoefler H, Rauch HJ, Kerl H, Denk H. New immunocytochemical observations with diagnostic significance in cutaneous neuroendocrine carcinoma. Am J Dermatopathol 1984;6:525-30.
35. Shah IA, Netto D, Schlageter MO, Muth C, Fox I, Manne RK. Neurofilament immunoreactivity in Merkel-cell tumors. A differentiating feature from small-cell carcinoma. Mod Pathol 1993;6:3-9.
36. Gould VE, Lee I, Hammar SP. Neuroendocrine skin carcinoma coexpressing cytokeratin and neurofilament proteins. Ultrastruct Pathol 1985;9:83-90.
37. Tope WD, Sangüeza OP. Merkel cell carcinoma. Histopathology immunohistochemistry, and cytogenetic analysis. J Dermatol Surg Oncol 1994;20:648-52.
38. Arber DA, Weiss LM. CD57: a review. Appl Immunohistochem 1995;3:137-52.
39. Caro WA, Helwig EB. Cutaneous lymphoid hyperplasia. Cancer 1969;24:487-502.
40. Evans HL, Winkelmann RK, Banks PM. Differential diagnosis of malignant and benign cutaneous lymphoid infiltrates. A study of 57 cases in wich malignant lymphoma had been diagnosed or suspected in the skin. Cancer 1979;44:699-717.
41. Burke JS. Malignant lymphomas of the skin: their differentiation from lymphoid and non lymphoid cutaneous infiltrates that simulate lymphoma. Sem Diagn Pathol 1985;2:169-82.
42. Ralfkiaer E. Immunohistological markers for the diagnosis of cutaneous lymphomas. Sem Diagn Pathol 1991;8:62-72.
43. García CF, Weiss LW, Warnke RA et al. Cutaneous follicular lymphoma. Am J Surg Pathol 1985;10:454-63.
44. Chan VT, Godwin TA, Mouradian JA. Immunohistochemistry and gene rearrangement studies in the diagnosis of malignant lymphomas. Hum Pathol 1991;22:1249-57.
45. Segal GH. Assessment of B-cell clonality by the polymerase chain reaction: a pragmatic overview. Adv Anat Pathol 1996;3:195-203.
46. Weiss LM, Arber DA, Chang KL. CD45: a review. Appl Immunohistochem 1993;1:166-81.
47. Norton AJ, Ramsay AD, Smith SH, Beverley PCL, Isaacson PG. Monoclonal antibody (UCHL-1) that recognises normal and neoplastic T cells in routinely fixed tissues. J Clin Pathol 1986;39:399-405.
48. Poppema S, Hollema H, Visser L, Voss H. Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol 1987;127:418-29.
49. Cabeçadas JM, Isaacson PG. Phenotyping of T-cell lymphomas in paraffin-sections. Which antibodies? Histopathology 1991;19:419-24.
50. Chan KL, Arber DA, Weiss LM. CD20: a review. Appl Immunohistochem 1996;4:1-15.
51. Mason DY, Cordell J, Brawn M et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tisue samples. Blood 1995;86:1453-9.
52. Arber DA, Weiss LM. CD43: a review. Appl Immunohistochem 1993;1:88-99.
53. Mason DY, Cordell J, Brown M et al. Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol 1989;42:1194-200.
54. Weis LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t (14; 18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987;317:1185-9
55. Cerroni L, Kerl H. The use of monoclonal antibodies on paraffine sections in the diagnosis of cutaneous lymphoproliferative disorders. Dermatol Clin 1994;12:219-29.
56. Willemze R, Rijlaarsdam JU, Meijer CJLM. Are most primary cutaneous B-cell lymphomas «marginal cell-lymphomas?». Br J Dermatol 1995;133:950-4.
57. Slater DN. Malt and salt: the clue to cutaneous B-cell lymphoproliferative disease. Br J Dermatol 1994;131:557-61.
58. Burg G, Schmid MH, Küng E, Dommann S, Dummer R. Semi malignant («pseudolymphomatous») cutaneous B-cell lymphomas. Dermatol Clin 1994;12:399-407.
59. Kurtin PJ, Di Caudo DJ, Habermann TM, Chen MG, Su WPD. Primary cutaneous large cell lymphomas: morphologic immunophenotypic and clinical features of 20 cases. Am J Surg Pathol 1994;18:1183-91.
60. Willemze R, Beljaards RC, Meijer CJLM, Rijlaarsdam JR. Classification of primary cutaneous lymphomas. Dermatology 1994;189:8-15.
61. Willemze R, Meijer CJLM, Scheffer E, Van der Putte SCJ. Diffuse large cell lymphoma of follicular center cell origin presenting in the skin. A clinicopathologic and immunologic study of 16 patients. Am J Pathol 1987;126:325-33.
62. Rest EB, Horun TD. Immunophenotypic analysis of benign and malignant cutaneous infiltrates. Clin Dermatol 1991;9:261-72.
63. Ritter JH, Adesokan PN, Fitzgibbon JF, Wick MR. Paraffin section immunohistochemistry as an adjunct to morphologic analysis in the diagnosis of cutaneous lymphoid infiltrates. J Cutan Pathol 1994;21:481-93.
64. Cerroni L, Volkenandt M, Pieger E, Snover HP, Kerl H. Bcl-2 protein expression and correlation with interchromosomal 14; 18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994;102:231-5.
65. Dummer R, Michie SA, Kell D et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995;22:11-7.
66. Willenze R, Beljaards RC, Rijlaarsdam U. Classification of primary cutaneous large cell lymphomas. Dermatol Clin 1994;12:361-73.
67. Chot A, Kaserer K, Augustin I et al. Ki-1 positive large cell lymphoma, a clinicopathologic study of 41 cases. Am J Surg Pathol 1990;14:439-48.
68. Beljaards RC, Meijer CJLM, Scheffer E et al. Prognostic significance of CD30 (Ki-1/BerH2) expression of primary cutaneous large-cell lymphomas of T-cell origin, a clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989;135:1169-78.
69. Chan JKC. CD30+ (Ki1) lymphoma: T (2; 5) translocation the implicated genes, and more... Adv Anat Pathol 1995;2:99-104.
70. Beljaards RC, Meijer CJLM, Scheffer E et al. Primary cutaneous CD30- positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favourable prognosis. Cancer 1993;71:2097-104.
71. Chang KL, Arber DA, Weiss LM. CD30: a review. Appl Immunohistochem 1993;14:244-55.
72. Charalambous C, Singh N, Isaacson PG. Inimunohistochemical analysis of Hodgkin's disease using microwave heating. J Clin Pathol 1994;46:1085-8.
73. Frierson HF, Bellafiore FJ, Gaffey MJ, McCary WS, Innes DJ, Williams ME. Cytokeratin in anaplastic large cell lymphoma. Mod Pathol 1994;7:317-21.
74. Lasota J, Hyjet EK, Koo CH, Blonski J, Miettinen M. Cytokeratin-positive large-cell lymphomas of B-cell linage. A study of five phenotyphically unusual cases verified by polimerase chain reaction. Am J Surg Pathol 1996;20:346-54.
75. Shiota M, Fujimoto J, Takenaga M et al. Diagnosis of t (2; 5) (p23; q35)-associated Ki-1 lymphomas with immunohistochemistry. Blood 1994;84:3648-52.
76. Beuchner SA, LI CY, Su WP. Leukemic cutis. A hystopathologic study of 42 cases. Am J Dermatopathol 1985;7:109-19.
77. Ratnam KV, Su WPD, Ziesmer SC, Li CY. Value of immunohistochemistry in the diagnosis of leukemia cutis. Study of 54 cases using paraffin-section markers. J Cutan Pathol 1992;19:193-200.
78. Van der Rijn M, Rouse RV. CD34: a review. Appl Immunohistochem 1994;2:71-80.
79. Hanson CA, Ross CW, Schnitzer B. Anti-CD34 immunoperosidase steinig in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. Hum Pathol 1992;23:26-32.
80. Chilosi M, Pizzolo G. Review of terminal deoxynucleotidyl transferase. Byological aspects, methods of detection, and selected diagnostic applications. Appl Immunohistochem 1995;3:209-21.
81. Neiman RS, Barcos M. Berard C, Bonner H, Mann R, Rydell RE, Bennett JM. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 1981;48:1426-37.
82. Mason DY, Taylor CR. The distribution of muramidase (lysozyme) in human tissues. J Clin Pathol 1975;28:124-32.
83. Traweek ST, Arber DA, Rappaport H, Brynes RK. Extramedullary myeloid cell tumors: an immunohistochemical and morphologic study of 28 cases. Am J Surg Pathol 1993;17:1011-9.
84. Ralfkiaer E, Pulford KAF, Lauritzen AF, Armstrom S, Guldhammer B, Mason DY. Diagnosis of acute myeloid leukemia with the use of monoclonal anti-neutrophil elastase (NP-57) reactive with routinely processed biopsy samples. Histopathology 1989;14:637-43.
85. Pinkus GS, Pinkus JL. Myeloperoxidase: a specific marker for myeloid cells in paraffin sections. Mod Pathol 1991;4:733-41.
86. Wong KP, Chan JKC. Antimyeloperoxidase: antibody of choice for labeling of myeloid cells including diagnosis of granulocytic sarcoma. Adv Anat Pathol 1995;2:65-8.
87. Roth MJ, Medeiros LJ, Elenitoba-Johnson K, Kuchnio M, Jaffe LS, Stetler-Stevenson M. Extramedullary myeloid cell tumors: an immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch Pathol Lab Med 1995;119:790-8.
88. Ritter JH, Goldstein NS, Argenyi Z, Wick MR. Granulocytic sarcoma: an immunohistologic comparison with peripheral T-cell lymphoma in paraffin sections. J Cutan Pathol 1994;21:207-16.
89. Wick MR, Fitzgibbon JF, Swanson PE. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Sem Diagn Pathol 1993;10:148-58.
90. Kaye VN, Swanson PE. Evaluation of spindle cell tumors. Clin Dermatol 1991;9:217-26.
91. Manivel JC, Dehner LP, Wick MR. Nonvascular sarcomas of the skin. En: Wick MR (ed): Pathology of unusual malignant cutaneous tumors. New York, NY: Marcel Dekker Inc, 1985;211-79.
92. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants: a study 45 cases. Am J Surg Pathol 1989;13:358-73.
93. Kuwano H, Hashimoto H, Enjoji M. Atypical fibroxanthoma distinguishable from spindle cell carcinoma in sarcoma-like skin lesions. Cancer 1985;55:172-80.
94. Wick MR, Schwanson PE, Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. J Cutan Pathol 1988;15:201-7.
95. Azumi N, Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin and alcohol-fixed tumors. Am J Clin Pathol 1987;88:286-96.
96. Chan R, Edwards BF, Hu R et al. Characterization of two monoclonal antibodies in an immunohistochemical study of keratin 8 and 18 expression. Am J Clin Pathol 1988;89:472-80.
97. Gown AM, Vogel AM. Monoclonal antibodies two human intermediate filament proteins. III. Analysis of tumors. Am J Clin Pathol 1985;84:413-24.
98. Gown AM, Boyd HC, Chang V, Ferguson M, Reichler B, Tippens D. Smooth muscle cells can express cytokeratins to «simple» epithelium. Immunocytochemical and biochemical studies in vitro and in vivo. Am J Pathol 1988;132:223-32.
99. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD. Anomalous cytokeratin expression in malignant melanoma: one and two dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 1990;3:494-501.
100. Swanson PE, Dehner LP, Sirgi KE, Wick MR. Cytokeratin immunoreactivity in malignant tumors of bone and soft tissue. A reappraisal of cytokeratin as a reliable marker in diagnostic immunohistochemistry. Appl Immunohistochem 1994;2:103-12.
101. Van Muijen GNP, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 1987;57:359-69.
102. Chase DR, Enzinger FM, Weiss SW, Langloss JM. Keratin in ephitelioid sarcoma: an immunohistochemical study. Am J Surg Pathol 1984;8:435-41.
103. Corson JM, Weiss LM, Banks-Schlegel SP, Pinkus GS. Keratin proteins and carcinoembryonic antigen in synovial sarcoma: an immunohistochemical study of 24 cases. Hum Pathol 1984;15:615-21.
104. Anstey A, McKee P, Winson Jones E. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br j Dermatol 1993;129:359-71.
105. Bruining JA, Mihn MC, Barnhill RC. Desmoplastic melanomas. Histopathology 1992;20:197-205.
106. Anstey A, Cerio R, Ramnarain N, Orchard G, Smith N, Wilson Jones E. Desmoplastic malignant melanoma: an immunocytochemical study 25 cases. Am J Dermatopathol 1994;16:14-22.
107. Sáenz-Santamaría MC, García-Latasa JF, McNutt NS. Marcadores inmunohistoquímicos en el melanoma cutáneo. Actas Dermosifiliogr 1995;86:417-36.
108. Argenyi ZB, Cain C, Bromley C et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol 1994;16:233-40.
109. Ben-Izhak O, Stark P, Levy R, Bergman R, Lichtig C. Epithelial markers in malignant melanoma. A study of primary lesions an their metastases. Am J Dermatopathol 1994;16:241-6.
110. Silvis NG, Swanson PE, Manivel JC et al. Spindle-cell and pleomorphic neoplasms of the skin. Am J Dermatopathol 1988;10:9-19.
111. Ma CK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol 1992;97:483-7.
112. Rica A Jr, Cartun W, Zakowski MF. Atypical fibroxantoma: a study of 14 cases emphasizing the presence of Langerhans' histiocytes with implications for differential diagnosis by antibody panels. Am J Surg Pathol 1988;12:591-8.
113. Longacre T, Smoller BR, Rouse RV. Atypical fibroxantoma: multiple immunohistologic profiles. Am J Surg Pathol 1933;17:1199-209.
114. Pulford KA, Rigney EM, Micklen KJ et al. KP1-a new monoclonal antibody that detects a monocite/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol 1989;42:414-21.
115. Binder SW, Said JW, Shintaku IP, Pinkus GS. A histiocytespecific marker in the diagnosis of malignant fibrous histiocytoma. Use of monoclonal antibody KP-1 (CD68). Am J Clin Pathol 1992;97:759-63.
116. Tsang WY, Chan JK. KP1 (CD68) staining of granular cell neoplasms: is KP1 a marker for lysosomes rather than the histiocytic linage? Histopathology 1992;21:84-6.
117. Fachetti F, Bertalot G. Grigolato PC. KP1 (CD68) stainig of malignant melanomas. Histopatology 1991;19:141-5.
118. Leader M, Patel J, Collins M, Henry K. Anti-alpha 1-antichymotrypsin staining of 194 sarcomas, 38 carcinomas, and 19 malignant melanomas. Its lack of specificity as a tumor marker. Am J Surg Pathol 1987;11:133-9.
119. Ellis GL, Langloss JM, Heffner DK, Hyams VJ. Spindle-cell carcinoma of the aerodigestive tract. Am J Surg Pathol 1987;11:335-42.
120. Smith KJ, Skelton HG, Morgan AM, Barrett TL, Lupton GP. Spindle cell neoplasms coexpressing cytokeratin and vimentin (metaplastic squamous cell carcinoma). J Cutan Pathol 1992;19:286-93.
121. Swamon PE, Stanley NW, Scheithauer BW, Wick MR. Primary cutaneous leiomiosarcoma: a histological and immunohistochemical study of 9 cases, with ultrastructural correlation. J Cutan Pathol 1988;15:129-41.
122. Wesche WA, Fletcher CDM, Dias P, Houghton PJ, Parham DM. Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcoma. Am J Surg Pathol 1995;19:261-9.
123. Dias P, Dilling M, Houghton P. The molecular basis of skeletal muscle differentiation. Sem Diagn Pathol 1994;11:3-14.
124. Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM. Expression of myogenic regulatory proteins (myogenin and MioD1) in small blue round cell tumors of childhood. Am J Pathol 1995;147:1799-810.
125. Prescott RJ, Banerjee SS, Eyden BP, Haboubi NY. Cutaneous epithelioid angiosarcoma: a clinicopathologycal study of four cases. Histopatology 1994;25:421-9.
126. Nappi O, Wick MR, Pettinato G, Ghiselli RW, Swanson PE. Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma. Am J Surg Pathol 1992;16:429-38.
127. De Young BR, Wick MR, Fitzgibbon JF, Sirgi KE, Swanson PE. CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl Immunohistochem 1993;1:97-100.
128. Nakhleh RE, Wick MR, Rocamora A, Swanson PE, Dehner LP. Morphologic diversity in malignant melanomas. Am J Clin Pathol 1990;93:731-40.
129. Ordóñez N, Batsakis J. Comparison of Ulex europaeus I lectin and factor VIII-related antigen in vascular lesions. Arch Pathol Lab Med 1984;108:129-32.
130. Swanson PE, Wick MR. Immunohistochemical evaluation of vascular neoplasms. Clin Dermatol 1991;9:243-53.
131. Burgdorf WHC, Mukai K, Rosai J. Immunohistochemical identification of factor VIII related antigen in endothelial cells of cutaneous lesions of alleged vascular nature. Am J Clin Pathol 1981;75:167-71.
132. Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KG, Mason DY. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumors. J Clin Pathol 1992;45:143-8.
133. Partums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990;43:752-7.
134. Suzuki Y, Hashimoto K, Crissman J, Kanzaki T, Mishiyama S. The value of blood group-specific lectin and endothelial-associated antibodies in the diagnosis of vascular proliferations. J Cutan Pathol 1986;13:408-19.
135. Longacre TA, Rouse RV. CD31: a new marker for vascular neoplasms. Adv Anat Pathol 1994;1:16-20.
136. Aziza J, Mazerolles C, Selves J et al. Comparison of the reactivities of monoclonal antibodies QBEND10 (CD34) and BNH9 in vascular tumors. Appl Immunohistochem 1993;1:51-9.
137. Cohen PR, Rapini RP, Farhood AI. Expression of the human hepatopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors. J Cutan Pathol 1993;20:15-20.
138. Ramani P, Bradley NJ, Fletcher CDM. QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. Histopathology 1990;17:237-42.
139. Sirgi CE, Wick MR, Swanson PE. B72. 3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumors: adjunts in the recognition of endothelial neoplasms. Am J Surg Pathol 1993;17:179-85.
140. Traweek ST, Kandalaft PL, Mehta P, Battifora H. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991:96:25-31.
141. Sarkey EA, More L, Dhillon AP. QBEnd/10: a new immunostain for the routine diagnosis of Kaposi's sarcoma. J Pathol 1990;161:267-71.
142. Weiss SW, Nickoloff BJ. CD34 its expressed by distinctive cell population in peripheral nerve sheath tumours and related lesions. Am J Surg Pathol 1993;17:1039-45.
143. De Young BR, Swanson PE, Argenyi ZB et al. C31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. J Cutan Pathol 1995;22:215-22.
144. Jiménez-Acosta F, Poblet E, Báez O, Santana C. Antígenos endoteliales en el sarcoma de Kaposi: expresión de CD34, CD31, factor von Willebrand, Ulex europaeus-I y factor XIII a. Patología 1993;26:177-82.
145. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H-and Y-antigens: evaluations of the specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994;7:82-9.
146. Kamino H, Jacobson M. Dermatofibroma extending into the subcutaneous tissue. Differential diagnosis from dennatofibrosarcoma protuberans. Am J Surg Pathol 1990;14:1156-64.
147. Templeton SF. Evaluation for expression of factor XIIIa and CD34 is of practical value in the diagnosis of selected lesions of dermatofibroma and dermatofibrosarcoma protuberans. Adv Anat Pathol 1995;2:270-4.
148. Mosher DF, Schad PE, Vann JM. Cross-linking of collagen and fibronectin by factor XIIIa. J Biol Chem 1980;255:1181-8.
149. Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIIIa is synthesized and expressed on the surface of U937 cells and alveolar macrophages. Blood 1987;69:778-85.
150. Nemes Z, Thomazy V, Adany R, Muszbek L. Identification of histiocytic reticulum cells by the immunohistochemical demonstration of factor XIII (FXIIIa) in human lymph nodes. J Pathol 1986;149:121-32.
151. Adany R, Glukhova MA, Kabakov AY, Muszbek L. Characterisation of connective tissue cells containing factor XIII subunit a. J Clin Pathol 1988;41:49-56.
152. Cerio R, Spaull J, Oliver GF, Jones EW. A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin. Am J Dermatopathol 1990;12:221-33.
153. Headington JT. The dermal dendrocyte. Adv Dermatol 1986;1:159-71.
154. Cerio R, Spaull J, Willson Jones E. Identification of factor XIIIa in cutaneous tissue Histopalhology 1988;13:362-3.
155. Cerio R, Spaull J, Jones EW. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol 1989;120:197-206.
156. Altman DA, Nickoloff BJ, Fivenson DP. Differential expression of factor XIIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol 1993;20:154-8.
157. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993;15:429-34.
158. Cerio R, Griffiths CEM, Cooper KD, Nickoloff BJ, Headington JT. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989;121:421-31.
159. Calonje E, Fletcher CDM. Cutaneous fibrohistiocytic tumors: an update. Adv Anat Pathol 1994;1:2-15.
160. Aiba S, Tabata N, Ishii H, Ootani H, Tagami II. Dermato-fibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992;127:79-84.
161. Prieto VG, Reed JA, Shea CR. CD34 immunoreactivity distinguishes between scar tissue and residual tumour in reexcisional specimens of dermatofibrosarcoma protuberans. J Cutan Pathol 1994;21:324-9.
162. Fitzgibbon JF, Henner MS, Swanson PE, Wick MR. CD34 stainig of cutaneous fibrohistiocytic tumors. Specificity and sensitivity as a tumor marker for dermatofibrosarcoma protuberans. J Cutan Pathol 1992;19:522-9.
163. Braithwaite C, Shuster S. Dermatofibrosarcoma protuberans. A critical reappraisal of the role of immunohistochemical stains for diagnosis. Appl Immunohistochem 1994;2:36-41.
164. Zelger B, Sidoroff A, Stancenzl U et al. Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans, a clinicopathologic comparison. Am J Surg Pathol 1994;18:677-86.
165. Fitzpatrick JE. The histologic diagnosis of intracpithehal pagetoid neoplasms. Clin Dermatol 1991;9:255-9.
166. Reed W, Oppedal BR, Eeg-Larsen T. Immunohistology is valuable in distinguishing between Paget's disease, Bowen's disease and superficial spreading malignant melanoma. Histopathology 1990;16:583-8.
167. Guldhammer B, Norgaard T. The differential diagnosis of intraepidermal malignant lesions using immunohistochemistry. Am J Dermatopathol 1986;8:295-301.
168. Jones RE Jr, Ackerman AB. Extramammary Paget's disease: a critical reappraisal. Am J Dermatopathol 1979;1:101-32.
169. Guarner J, Cohen C, De Rose PB. Histogenesis of extramammary an mammary Paget cells. An immunohistochemical study. Am J Dermatopathol 1989;11:313-8.
170. González Cámpora R. Proliferaciones epiteliales intraepidérmicas. Piel 1990;5:131-8.
171. Ordóñez NG, Await H, Mackay B. Mammary and extramammary Paget's disease: an immunohistochemical and ultrastructural study. Cancer 1987;59:1173-83.
172. Nagle RB, Lucas DO, McDaniel M et al. Paget's cells. New evidence linking mammary and extramammary Paget cells to a common cell fenotype. Am J Clin Pathol 1985;83:431-8.
173. Suster S. Clear cell tumors of the skin. Sem Diagn Pathol 1996;13:40-58.
174. Heyderman E, Graham RM, Chapman DV et al. Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology 1984;8:423-34.
175. Penneys NS, Nadji M, McKinney C. Carcinoembryonic antigen present in human eccrine sweat. J Am Acad Dermathol 1981;4:401-3.
176. Wood WS, Hegedus C. Mammary Paget's disease and intraductal carcinoma. Histopathologic, histochemical, and immunocytochemical composition. Am J Dermatopathol 1988;10:183-8.
177. Mazoijian G, Pinkus GS, Davis S. Immunohistochemistry of a breast gross cystic disease fluid protein (GCDFP-15) a marker of apocrine epithelium and breast carcinoma with apocrine features. Am J Pathol 1983;110:10541.
178. Tsubura A, Senzaki H, Saski M et al. Immunohistochemical demonstration of breast derived and/or carcinoma-associated glycoproteins in normal skin appendages and their tumors. J Cutan Pathol 1992;19-73-9.
179. Ichikawa E, Watanabe S, Otsuka F. Immunohistochemical localization of keratins and involucrin in solar keratosis and Bowen's disease. Am J Dermatopathol 1995;17:151-7.
180. Zelger B, Sidoroff A, Höpfl R, Öfner D, Jasani B, Schmid KW. Metallothioneim expression in nonmelanoma skin cancer: an immunocytochemical study. Appl Immunohistochem 1994;2:254-60.
181. Zelger B, Hittmair A, Schir M et al. Immunocytochemically demonstrated metalothionein expression in malignant melanomas. Histopathology 1993;23:257-64.
182. Penneys NS, Shapiro S. CD44 expression in Merkel cell carcinoma may correlate with risk of metastases. J Cutan Pathol 1994;21:22-6.
183. Prieto VG, Reed JA, McNutt NS, Bogdany JK, Lugo J, Shea CR. Differential expression of CD44 in malignant cutaneous epithelial neoplasms. Am J Dermatopathol 1995;17:447-651.
184. Cohen SM, Purtilo DT, Ellwein LB. Ideas in pathology. Pivotal role of in creased cell proliferation in human carcinogenesis. Mod Pathol 1991;4:371-82.
185. Coon JS, Landay AL, Weinstein RS. Advances in flow cytometry for diagnostic pathology. Lab Invest 1987;57:453-79.
186. Dervan PA, Gilmartin LG, Loftus BN, Carney DN. Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki-67 scores. Am J Clin Pathol 1989;92:401-7.
187. Hall PA, Levison DA, Woods AL et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulatet expression in some neoplasms. J Pathol 1990;162:285-94.
188. Dervan PA, Magee HM, Buckley C, Carney DN. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 1992;97:521-8.
189. Kelleher L, Magee HM, Dervan PA. Evaluation of cell-proliferation antibodies reactive in paraffin sections. Appl Immunohistochem 1994;2:164-70.
190. Garcia RL, Coltrera MD, Gown AM Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues comparison with flow cytometric analysis. Am J Pathol 1989;134:733-9.
191. Cattoretti G, Becker MHG, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
192. Culotta E, Koshlan DE. Molecule of the year: p53 sweeps through cancer research science 1993;262:1958-61.
193. Batsakis JG, El-Naggar AK. p53: fifteen years after discovery. Adv Anat Pathol 1995;2:71-88.
194. Battifora H. p53 immunohistochemistry a word of caution. Hum Pathol 1994;25:435-7.
195. Pizarro Redondo A. ¿Qué significa una inmunotinción positiva para la proteína p53? Piel 1995;10:57-9.
196. Stone CH, Lynch EF, Linden MD, Kubus JJ, Zarbo RJ. Immunocytochemical evaluation of proliferating cell nuclear antigen, Ki-67 (MIB-1), and p53 in predicting survival of primary and metastatic malignant melanomas. Appl Immunohistochem 1996;4:25-33.